Efficacy and safety of a novel acetylcholinesterase inhibitor octohydroaminoacridine in mild-to-moderate Alzheimer's disease: a Phase II multicenter randomised controlled trial | Zendy

Shifu Xiao | Zendy; Tao Wang | Zendy; Xiuqiang Ma | Zendy; Yingyi Qin | Zendy; Xia Li | Zendy; Zhongxin Zhao | Zendy; Xueyuan Liu | Zendy; Xiaoping Wang | Zendy; Hengge Xie | Zendy; Qinpu Jiang | Zendy; Li Sun | Zendy; Benyan Luo | Zendy; Lan Shang | Zendy; Weixian Chen | Zendy; Yan Bai | Zendy; Muni Tang | Zendy; Maolin He | Zendy; Lan Wu | Zendy; Qilin Ma | Zendy; Deren Hou | Zendy; Jia He | Zendy

Open Access

Efficacy and safety of a novel acetylcholinesterase inhibitor octohydroaminoacridine in mild-to-moderate Alzheimer's disease: a Phase II multicenter randomised controlled trial

Author(s) -

Shifu Xiao,

Tao Wang,

Xiuqiang Ma,

Yingyi Qin,

Xia Li,

Zhongxin Zhao,

Xueyuan Liu,

Xiaoping Wang,

Hengge Xie,

Qinpu Jiang,

Li Sun,

Benyan Luo,

Lan Shang,

Weixian Chen,

Yan Bai,

Muni Tang,

Maolin He,

Lan Wu,

Qilin Ma,

Deren Hou,

Jia He

Publication year - 2017

Publication title -

age and ageing

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 2.014

H-Index - 143

eISSN - 1468-2834

pISSN - 0002-0729

DOI - 10.1093/ageing/afx045

Subject(s) - medicine , placebo , adverse effect , clinical endpoint , post hoc analysis , clinical trial , donepezil , randomized controlled trial , clinical global impression , multicenter trial , alzheimer's disease , multicenter study , dementia , disease , pathology , alternative medicine

inhibition of acetylcholinesterase (AChE) has been a effective treatment for Alzheimer's disease (AD). Octohydroaminoacridine, a new AChE inhibitor, is a potential treatment for AD.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research